Inserting And Removing Central Venous Catheters Cause Significant Discomfort In Cancer Patients And At Times Is Unnecessary

Use of Mino-Lok™ to disinfect CVCs could avoid patient discomfort while providing an effective alternative in the treatment of Central Line Associated Bloodstream infections (CLABSIs).

CRANFORD, N.J., Nov. 14, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, noted that a recent paper presented at the Infectious Disease Society of America (IDSA) meeting in early October (ID Week - 2017) showed that as many as half of the patients having their central venous catheters (CVCs) removed or inserted experience distress and/or catheter threading pressure, and about a third felt these symptoms to be severe.

Mr. Myron Holubiak, Chief Executive Officer of Citius, commented "We have believed for some time now, that the physical process of inserting and removing CVCs cause patients significant discomfort, and that having an anti-infective solution that could adequately disinfect a CVC thereby avoiding the removal and insertion of a new CVC would be of great benefit to patients from a symptom burden point of view."

There are currently no approved therapies to salvage infected central venous catheters.  CLABSIs are responsible for mortality rates up to 25% in some patients, and contribute to significant morbidities. Citius is currently enrolling patients for a phase 3 trial of Mino-Lok in the United States.

About Citius Pharmaceuticals, Inc.

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs; by using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.


Andrew Scott
Vice President, Corporate Development
(O) 908-967-6676


View original content:

SOURCE Citius Pharmaceuticals, Inc.